Vasopressin-2 receptor antagonist peptides and uses thereof

The USPTO has granted Patent US12595288B2 to Commissariat à l'Énergie Atomique et aux Énergies Alternatives covering vasopressin-2 receptor antagonist peptides. The patent protects peptide sequences with at least 80% amino acid identity to SEQ ID NO. 1, with specific modifications at variable positions enabling therapeutic applications. The grant includes 14 claims.

Methods to Decrease Impurities from Recombinant Protein Manufacturing Processes

The USPTO granted Patent US12595294B2 to Hoffmann-La Roche Inc. on April 7, 2026. The patent covers methods for reducing non-aggregate produce-related impurities (NAPRIs) in buffered solutions of monoclonal antibodies using synthetic depth filters. Inventors are Marc Pompiati and Christoph Feistl, with 15 claims in the granted patent.

Anti-NGF Antibody and Antigen-Binding Fragment Patent Grant

USPTO granted Patent US12595298B2 to XIYUAN ANJIAN MEDICINE (SHANGHAI) CO., LTD. for an anti-NGF antibody and its antigen-binding fragment, covering the preparation method and therapeutic applications for NGF-mediated diseases. The patent includes 6 claims and was filed on August 2, 2021.

Fc Variants and IL-8 Antibodies Patent Grant

USPTO granted patent US12595299B2 to Chugai Seiyaku Kabushiki Kaisha covering Fc region variants with improved antigen binding in ion concentration-dependent manner, Fc variants with decreased binding to pre-existing anti-drug antibodies, and novel IL-8 antibodies for pharmaceutical use. The patent contains 17 claims and covers molecules derived from antibody engineering technology.

Anti-human P40 protein domain antibody and use thereof

USPTO granted Patent US12595300B2 to Akeso Biopharma, Inc. covering an anti-human P40 protein domain antibody for treating autoimmune diseases. The patent includes 20 claims with specific amino acid sequences for heavy and light chain variable regions (SEQ ID NOs 1, 24 for heavy chain; SEQ ID NOs 6, 11, 13, 15, 17, 25 for light chain).

LMP-1 Expressing Cells and Methods of Use Thereof - Dana-Farber Cancer Institute

Dana-Farber Cancer Institute, Inc. has been granted USPTO Patent US12595285B2 covering immunogenic cells expressing LMP1 and methods of use for cancer treatment and T cell activation. The patent, with 15 claims, names Baochun Zhang, Il-Kyu Choi, and Zhe Wang as inventors, with an application filing date of May 13, 2022.

P2X3 receptor antagonist patent, Beijing Tide Pharma, 6 claims

P2X3 receptor antagonist patent, Beijing Tide Pharma, 6 claims

Heterocyclic GLP-1 agonists

USPTO granted patent US12595264B2 to Gasherbrum Bio, Inc. on April 7, 2026, covering heterocyclic GLP-1 receptor agonists of Formula (I), including pharmaceutical salts, solvates, and compositions. The patent names six inventors and contains 24 claims, with CPC classifications spanning heterocyclic chemistry (C07D 487/04), phosphorus compounds (C07F 9/6561), and pharmaceutical formulations (A61K 31/4985, A61K 38/26).

PRMT5 inhibitors for cancer, sickle cell, and HPFH treatment

USPTO granted patent US12595262B2 to Merck Sharp & Dohme LLC for PRMT5 inhibitor compounds and methods of treatment for cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin (HPFH). The patent covers 14 claims including compounds A through D and their pharmaceutical salts, esters, and prodrugs.

Inspection Device with ML Classification Using Temporal Images - NEC Corporation

The USPTO granted NEC Corporation Patent US12597112B2 for an inspection device that classifies temporal captured images of target objects into groups using machine learning, recognizes images within each group, and integrates determination results to output a final classification result. The patent covers classification means, recognition means, and integration means for processing sequential image data.